Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01585038 · ClinicalTrials.gov registry record · Phase 4
Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT01585038 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 40 participants.
The verdict
NCT01585038, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the cardiovascular profiles of efavirenz and rilpivirine, which are two drugs used to treat HIV infection.
Interventions
- DRUG Efavirenz
- DRUG Rilpivirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01585038
The ClinicalTrials.gov registry entry for NCT01585038 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Efavirenz is the first listed.
NCT01585038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01585038 about?
NCT01585038 is a clinical study titled "Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress". The purpose of this study is to compare the cardiovascular profiles of efavirenz and rilpivirine, which are two drugs used to treat HIV infection.
What is the current status of trial NCT01585038?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2012-07. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01585038?
The interventions under investigation include: Efavirenz (DRUG), Rilpivirine (DRUG).
Who is sponsoring clinical trial NCT01585038?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.